The start of production for the INSPIRA ART100 medical device represents a critical milestone for Inspira Technologies, indicating progress in its product development and potential market entry. This development is likely to be viewed positively by investors, as it demonstrates the company's advancement towards commercialization, pending regulatory approval. The direct involvement in manufacturing and the pending FDA clearance are key factors that could influence investor sentiment and potentially impact the stock price positively in the short term.